Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Utah Medical Products (UTMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to 22.98%.

  • Utah Medical Products' EBITDA Margin fell 269400.0% to 22.98% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.48%, marking a year-over-year decrease of 89200.0%. This contributed to the annual value of 30.87% for FY2024, which is 50100.0% down from last year.
  • According to the latest figures from Q3 2025, Utah Medical Products' EBITDA Margin is 22.98%, which was down 269400.0% from 48.99% recorded in Q2 2025.
  • In the past 5 years, Utah Medical Products' EBITDA Margin registered a high of 51.17% during Q4 2022, and its lowest value of 9.65% during Q4 2024.
  • In the last 5 years, Utah Medical Products' EBITDA Margin had a median value of 29.32% in 2024 and averaged 31.18%.
  • The largest annual percentage gain for Utah Medical Products' EBITDA Margin in the last 5 years was 265500bps (2024), contrasted with its biggest fall of -359600bps (2024).
  • Over the past 5 years, Utah Medical Products' EBITDA Margin (Quarter) stood at 32.1% in 2021, then soared by 59bps to 51.17% in 2022, then decreased by -11bps to 45.62% in 2023, then crashed by -79bps to 9.65% in 2024, then soared by 138bps to 22.98% in 2025.
  • Its EBITDA Margin stands at 22.98% for Q3 2025, versus 48.99% for Q2 2025 and 38.71% for Q1 2025.